Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study.

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICI) have improved the therapeutic arsenal in outpatient oncology care; however, data on necessity of hospitalizations associated with immune-related adverse events (irAEs) are scarce. Here, we characterized hospitalizations of patients undergoing ICI, from the prospective cohort study of the immune cooperative oncology group (ICOG) Hannover.

Methods

Between 12/2019 and 06/2022, 237 patients were included. Clinical data and characteristics of ICI were collected during a 6-month observation period after the initiation of therapy. Descriptive statistics and Kaplan-Meier statistics were administered.

Results

During the observation period, 30/237 patients were hospitalized (HA(+)). Most common underlying tumor entities were malig

SUBMITTER: Wiegmann JP 

PROVIDER: S-EPMC11761430 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature